Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: kanta who wrote (278)	10/7/2000 9:09:00 AM
From: flatsville	Respond to of 340

kanta- teva shares are optionable: quote.yahoo.com I've heard many of the same rumors re: the split myself, but have not yet looked at the details. No help here at this time. Can someone else answer kanta's split questions?

To: kanta who wrote (278)	2/28/2001 2:58:58 AM
From: Dorine Essey	Respond to of 340

Market Report -- In Play (TEVA) February 27, 2001 11:26:00 AM ET Teva Pharm (TEVA) 64 7/16 +2 1/4 (+3.6%): -- Technical -- Has broken through its 50/100/200 moving averages in early week action but has stopped shy of its 2001 recovery high (also a retracement target) at 66. Is overextended short term but no intraday damage while support at 63 is intact. Broad consolidation range provides next resistance between 67-69. Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.

To: kanta who wrote (278)	7/25/2001 7:15:19 AM
From: Dorine Essey	Respond to of 340

Teva impresses investors with higher than expected profits Globes correspondent 25.07.2001 11:45 Teva (Nasdaq: TEVA) today reported net profits for the second quarter of $64 million or $0.47 per share, representing increases over last year of 41% and 38%, respectively. The profit per share was significantly higher than market expectations of $0.42. Second quarter revenue of $514 million was 16% higher than revenue of $443 million that was recorded for the same period last year. North American sales accounted for 63% of total second quarter revenue, Europe for 21%, Israel for 12%, with sales in the rest of the world accounting for 4%. Teva chief operating officer Israel Makov said, “We are very pleased to report results that marked another period of robust growth at Teva. These results validate our strategy of pursuing leadership in the generic industry through the introduction and execution of well-planned activities that are having a positive impact on our sales and overall profitability.” Makov added, “We are especially proud of developments in our revenue mix, which saw this quarter's 16% increase in sales driven not only by Copaxone but also by increased sales of our existing generic products.” Copaxone is Teva’s drug for the treatment of multiple sclerosis. Global sales of Copaxone continued to grow at more than twice the market rate and amounted to a record $91 million, up 54% from the comparable quarter in 2000 and up 24% from the first quarter 2001. North America accounted for 84% of Copaxone sales. Teva said that the registration of Copaxone in Europe, under the mutual recognition procedure, was expected to be completed later this year. During the quarter Teva launched two products and received tentative and final approvals from the FDA for five products. Teva said its board of directors was recommended to declare a regular cash dividend of NIS 0.27 (approximately $0.064 ) per ADR for the second quarter of 2001. The board will meet on August 13, 2001. Teva is among the top 40 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 85% of Teva's sales are outside Israel, mainly in North America and Europe. In late-morning trading, Teva shares are 1.2% higher in Tel Aviv, on an active NIS 20 million turnover. Published by Israel's Business Arena on 25 July, 2001

To: kanta who wrote (278)	8/15/2001 10:01:48 AM
From: Dorine Essey	Respond to of 340

Where is everyone. TEVA on a tear. Are you all missing the ride? Notice of Conference Call for TEVA PHARMACEUTICAL INDUSTRIES LTD. (NASDAQ: TEVA) You are cordially invited to participate in a conference call with the management of Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) to review the Company’s recent corporate Announcments. Wednesday, August 15 , 2001 10:30 a.m. Eastern Time Sincerely, Dorit Meltzer Director, Investor Relations In order to participate in the conference call: • For those individuals dialing in from the UNITED STATES & CANADA, please dial 877-370-1460 , for international callers dial +1 706-679-3312 just prior to 10:30 a.m. Eastern time and give the operator the Pass Code: “TEVA”. • For those individuals dialing in from ISRAEL, please dial: 03-9292810 just prior to 17:30 Israel time and give the operator the Pass Code: “TEVA”. • For those individuals dialing in from the UNITED KINGDOM, please dial: 0-800-169-9043, just prior to 15:30 U.K. time and give the operator the Pass Code: “TEVA”. • A replay of the call will be available until midnight, Eastern Time, Monday, August 20, 2001. From the USA please dial 800-642-1687, for international callers dial +1 706-645-9291. The Pass Code to access the call is “1612385”. For further assistance please contact Dorit Meltzer of Teva at 972-3-926-7554, dorit.meltzer@teva.co.il. Thank you for your interest and participation.